No headlines found.
Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
Globe Newswire (Thu, 26-Feb 6:33 AM ET)
Enovis Announces Fourth Quarter and Full Year 2025 Results
Globe Newswire (Thu, 26-Feb 6:10 AM ET)
Globe Newswire (Tue, 3-Feb 8:00 AM ET)
Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th
Globe Newswire (Fri, 23-Jan 8:30 AM ET)
Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Thu, 8-Jan 7:30 AM ET)
Enovis Appoints Oliver Engert as Chief Administrative Officer
Globe Newswire (Mon, 5-Jan 4:15 PM ET)
Enovis Corp is a medical technology manufacturer and distributor of medical devices used in reconstructive surgery, rehabilitation, pain management, and physical therapy. Its products support patient care from injury prevention through post-surgical or post-injury rehabilitation and treatment of degenerative conditions. The company's reportable segments include Prevention & Recovery and Reconstructive segments. The majority of revenueis derived from the Prevention & Recovery segment, which includes products that are used by orthopedic specialists, primary care physicians, physical therapists, chiropractors, athletic trainers and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformitiesand sports-related injuries.
Enovis trades on the NYSE stock market under the symbol ENOV.
As of April 2, 2026, ENOV stock price declined to $22.64 with 570,829 million shares trading.
ENOV has a beta of 1.75, meaning it tends to be more sensitive to market movements. ENOV has a correlation of 0.29 to the broad based SPY ETF.
ENOV has a market cap of $1.29 billion. This is considered a Small Cap stock.
Last quarter Enovis reported $576 million in Revenue and $.95 earnings per share. This fell short of revenue expectation by $-7 million and exceeded earnings estimates by $.12.
In the last 3 years, ENOV traded as high as $66.14 and as low as $21.00.
The top ETF exchange traded funds that ENOV belongs to (by Net Assets): IJR, VTI, VB, IWM, VBR.
ENOV has underperformed the market in the last year with a price return of -39.1% while the SPY ETF gained +18.2%. ENOV has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.0% and -1.3%, respectively, while the SPY returned -3.6% and -0.6%, respectively.
ENOV support price is $22.44 and resistance is $24.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENOV shares will trade within this expected range on the day.